Monsanto: Anderson must uproot Bayer’s perennial problem - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
FT商学院

Monsanto: Anderson must uproot Bayer’s perennial problem

New chief needs to signal to investors whether a restructuring is likely

Bayer’s 2018 acquisition of US crop science company Monsanto is the takeover that just keeps on taking. This week’s €2.5bn impairment charge adds to already extensive financial damage. It will reinvigorate activist demands for a break-up.

Bayer paid $65bn for Monsanto assets that included a glyphosate weedkiller called Roundup. Management initially underestimated the high cost of an accompanying health scare, as managements typically do. Allegations that Roundup is carcinogenic have prompted numerous lawsuits.

Bayer trades at a depressed enterprise valuation of about 7 times forward ebitda. Change may now be in the air. Werner Baumann, the chief executive responsible for the Monsanto purchase, has stepped aside after a long period of poor share price performance. Replacement Bill Anderson started last month. As a former Roche executive, his expertise is drugs, not weedkillers.

A couple of things look odd about the impairment. First, it is relatively small, given that Bayer has about €39bn of goodwill on its balance sheet, more than half of which derives from the Monsanto acquisition. Second, Bayer blames a weak glyphosate market, which might be a temporary phenomenon, for the writedown. About 60 per cent of world sales are generic products, most of which are made in China.

Anderson will hopefully substitute signal for noise when he presents earnings on August 8. He should signal whether a restructuring is likely. Activists Inclusive Capital and Bluebell have called for this. They favour a spinout of the crop science unit, a business that troubles environmental, social and governance investors.

That would make sense. Even at 10 times next year’s ebitda, a sixth cheaper than rivals FMC and Corteva, Bayer’s crop science unit should be worth about €60bn, 2024 Visible Alpha estimates imply — albeit undiscounted for a long tail of legal claims. Compare that with the group’s total enterprise value of €86bn.

Bayer has argued that cash flow from crop science and its consumer health unit help fund its growing pharmaceuticals pipeline. But Bayer’s persistently low multiple against agrochemical and pharma peers underscores the need for change.

Anderson wishes to boost pharma, for example, by removing centralised research budgeting. But that could take years to lift the group’s low valuation. Like all incoming bosses, he has a brief window to cut loose a problem division. He should exploit it.

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

一周新闻小测:2024年11月16日

您对本周的全球重大新闻了解如何?来做个小测试吧!

大英博物馆馆长库利南:“我的出发点是一切皆有可能”

新任馆长谈世界上最大的文化机构之一的转型、去年的盗窃丑闻--以及帕台农神庙大理石浮雕可能发生的情况。

伪装成货币政策的贸易保护主义是有害的

不如只制定正确的宏观政策,对美元置之不理?

苹果推高了爱尔兰信用评级展望

事实证明,被迫接受苹果公司支付的130亿欧元欠税也是一件好事。

特朗普的内阁人选:当选总统政府的关键人物

美国政界对一些候选人感到震惊,他们仍需得到参议院的确认。

台积电获得116亿美元补贴,美国芯片法案面临不确定的未来

拜登政府正在推动在特朗普重新入主白宫之前分配资金。
设置字号×
最小
较小
默认
较大
最大
分享×